| scholarly article | Q13442814 |
| P50 | author | Petros P Sfikakis | Q91233531 |
| P2093 | author name string | George D Kitas | |
| Evrydiki Kravvariti | |||
| P2860 | cites work | Open-Label Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: 6-Month Results From a Controlled Cohort Study. | Q53833137 |
| Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. | Q55005295 | ||
| Nocebo effects, patient-clinician communication, and therapeutic outcomes | Q56775265 | ||
| Positively Framed Risk Information in Patient Information Leaflets Reduces Side Effect Reporting: A Double-Blind Randomized Controlled Trial | Q57800842 | ||
| Nocebos in rheumatology: emerging concepts and their implications for clinical practice | Q58561333 | ||
| Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition s | Q63197656 | ||
| Somatic style and symptom reporting in rheumatoid arthritis | Q78235365 | ||
| Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis | Q81460890 | ||
| Induction of nocebo and placebo effects on itch and pain by verbal suggestions | Q83480491 | ||
| Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation | Q85366029 | ||
| Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study | Q87982475 | ||
| Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations | Q88041740 | ||
| Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review | Q90517623 | ||
| Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization | Q91055676 | ||
| Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey | Q91120963 | ||
| The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies | Q91679455 | ||
| Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data | Q31019795 | ||
| When words are painful: unraveling the mechanisms of the nocebo effect | Q31106595 | ||
| Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines | Q34131674 | ||
| Overt versus covert treatment for pain, anxiety, and Parkinson's disease | Q34359487 | ||
| Nocebo hyperalgesia: how anxiety is turned into pain | Q34688413 | ||
| A Neural Mechanism for Nonconscious Activation of Conditioned Placebo and Nocebo Responses | Q36098822 | ||
| Human brain mechanisms of pain perception and regulation in health and disease. | Q36175106 | ||
| Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review | Q36374308 | ||
| Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis | Q37476820 | ||
| A systematic review of adverse events in placebo groups of anti-migraine clinical trials | Q37603565 | ||
| Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study | Q37616966 | ||
| Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. | Q37698663 | ||
| Nocebo in fibromyalgia: meta‐analysis of placebo‐controlled clinical trials and implications for practice | Q37942656 | ||
| Nocebo in Headaches: Implications for Clinical Practice and Trial Design | Q37970944 | ||
| Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. | Q38375767 | ||
| Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice | Q38540866 | ||
| Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial | Q38787053 | ||
| Lessons Learned From Nocebo Effects in Clinical Trials for Pain Conditions and Neurodegenerative Disorders | Q38825910 | ||
| Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten | Q39037126 | ||
| The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes | Q39150999 | ||
| Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study | Q40184147 | ||
| A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry | Q40214597 | ||
| Minimizing nocebo effects by conditioning with verbal suggestion: A randomized clinical trial in healthy humans. | Q41074135 | ||
| A systematic review of sex differences in the placebo and the nocebo effect | Q41301771 | ||
| Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians | Q42013744 | ||
| Nocebo effects in clinical studies: hints for pain therapy | Q42376620 | ||
| Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans | Q42858321 | ||
| Use of ClinicalTrials.gov to Estimate Condition-Specific Nocebo Effects and Other Factors Affecting Outcomes of Analgesic Trials | Q44271031 | ||
| Development of the Stanford Expectations of Treatment Scale (SETS): A tool for measuring patient outcome expectancy in clinical trials | Q45181057 | ||
| Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance | Q47176097 | ||
| Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France | Q47226642 | ||
| Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. | Q47596946 | ||
| Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab | Q47633961 | ||
| Pain anticipation: an activation likelihood estimation meta-analysis of brain imaging studies | Q48404113 | ||
| Human Amygdala Activation during Conditioned Fear Acquisition and Extinction: a Mixed-Trial fMRI Study | Q48453514 | ||
| Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. | Q48473429 | ||
| Influence of Morphine and Naloxone on Pain Modulation in Rheumatoid Arthritis, Chronic Fatigue Syndrome/Fibromyalgia, and Controls: A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study | Q49077767 | ||
| The nocebo effect challenges the non-medical infliximab switch in practice | Q49721192 | ||
| Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis | Q49903656 | ||
| Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results | Q50034734 | ||
| Pain facilitation and pain inhibition during conditioned pain modulation in fibromyalgia and in healthy controls | Q50523124 | ||
| Using Sherlock and ClinicalTrials.gov data to understand nocebo effects and adverse event dropout rates in the placebo arm. | Q52882636 | ||
| P433 | issue | Suppl 1 | |
| P304 | page(s) | 63-68 | |
| P577 | publication date | 2019-05-31 | |
| P1476 | title | The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice | |
| P478 | volume | 30 |
Search more.